DoD Rare Cancers, Idea Development Award

The summary for the DoD Rare Cancers, Idea Development Award grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the Dept of the Army USAMRAA, which is the U.S. government agency offering this grant.
DoD Rare Cancers, Idea Development Award: The FY24 RCRP Idea Development Award promotes new ideas that are still in the early stages of development and have the potential to yield impactful data and new avenues of investigation. This award supports research supported by preliminary data that could lead to critical discoveries or major advancements that will accelerate progress toward eradicating deaths and suffering from rare cancers. Applications should include a well-formulated, testable hypothesis based on strong scientific rationale.Preliminary data with disease-specific rationale (may include correlative studies to ongoing clinical research) to support the feasibility of the research hypotheses and research approaches are required; however, these data do not necessarily need to be derived from studies of the proposed rare cancer type(s)/subtype(s) under study.Key elements of the Idea Development Award are as follows:• Impact: Research that has high potential impact may lead to major advancements and greatly improve outcomes for people with rare cancers.• Research Idea: Although the proposed research must have direct relevance to rare cancers, the required preliminary data, which may include unpublished results from the laboratory of the Principal Investigator (PI), research team, or collaborators named on the application, or may be from outside the rare cancers research field. Research should also be based on a sound scientific rationale that is established through logical reasoning and critical review and analysis of the literature.The application should clearly and explicitly articulate the project’s potential impact on rare cancers. Applications that demonstrate exceptional scientific merit but lack high potential impact do not meet the intent of the Idea Development Award.Innovative research involving nuclear medicine and related techniques to support early diagnosis, more effective treatment, and improved health outcomes of active-duty Service Members and their Families is encouraged. Such research could improve diagnostic and targeted treatment capabilities through noninvasive techniques and may drive the development of precision imaging and advanced targeted therapies.A congressionally mandated Metastatic Cancer Task Force was formed with the purpose of identifying ways to help accelerate clinical and translational research aimed at extending the lives of advanced state and recurrent patients. As a member of the Metastatic Cancer Task Force, CDMRP encourages applicants to review the recommendations (https://health.mil/Reference-Center/Congressional-Testimonies/2018/05/03/Metastatic-Cancer-Research) and submit research ideas to address these recommendations provided they are within the limitations of this funding opportunity and fit within the FY24 RCRP prioritiesCDMRP encourages research on health areas and conditions that affect women uniquely, disproportionately, or differently from men, including studies analyzing sex as a biologicalDOD FY24 Rare Cancers Idea Development Award 5variable. Such research should relate anticipated project findings to improvements in women’s health outcomes and/or advancing knowledge for women’s health.All projects should adhere to a core set of standards for rigorous study design and reporting to maximize the reproducibility and translational potential of clinical and preclinical research. The standards are described in SC Landis et al., 2012, A call for transparent reporting to optimize the predictive value of preclinical research, Nature 490:187-191 (https://www.nature.com/nature/journal/v490/n7419/full/nature11556.html). While these standards are written for preclinical studies, the basic principles of randomization, blinding, sample-size estimation, and data handling derive from well-established best practices in clinical studies.Applications from investigators within the military services and applications involving multidisciplinary collaborations among academia, industry, the military services, the U.S. Department of Veterans Affairs (VA), and other federal government agencies are highly encouraged. These relationships can leverage knowledge, infrastructure, and access to unique clinical populations that the collaborators bring to the research effort, ultimately advancing research that is of significance to Service Members, Veterans, and/or their Families. If the proposed research relies on access to unique resources or databases, the application must describe the access at the time of submission and include a plan for maintaining access as needed throughout the proposed research.Clinical trials are not allowed. A clinical trial is defined in the Code of Federal Regulations, Title 45, Part 46.102 (45 CFR 46.102) as a research study in which one or more human subjects are prospectively assigned to one or more interventions (which may include a placebo or another control) to evaluate the effects of the interventions on biomedical or behavioral health-related outcomes.Studies that do not seek to measure safety, effectiveness, and/or efficacy outcome(s) of an intervention are not considered clinical trials.
Federal Grant Title: DoD Rare Cancers, Idea Development Award
Federal Agency Name: Dept of the Army USAMRAA (DOD-AMRAA)
Grant Categories: Science and Technology and other Research and Development
Type of Opportunity: Discretionary
Funding Opportunity Number: HT942524RCRPIDA
Type of Funding: Grant
CFDA Numbers: 12.420
CFDA Descriptions: Information not provided
Current Application Deadline: September 26th, 2024
Original Application Deadline: September 26th, 2024
Posted Date: April 19th, 2024
Creation Date: April 19th, 2024
Archive Date: October 26th, 2024
Total Program Funding: $6,160,000
Maximum Federal Grant Award:
Minimum Federal Grant Award:
Expected Number of Awards: 11
Cost Sharing or Matching: No
Last Updated: April 19th, 2024
Applicants Eligible for this Grant
Unrestricted (i.e., open to any type of entity below), subject to any clarification in text field entitled "Additional Information on Eligibility"
Grant Announcement Contact
CDMRP Help Desk
Phone: 301-682-5507
Email: [email protected]
CDMRP Help Desk
Similar Government Grants
DoD Traumatic Brain Injury and Psychological Health, Translational Research Award
DoD Traumatic Brain Injury and Psychological Health, Focused Program Award
DoD Traumatic Brain Injury and Psychological Health, Health Services Research Award
DOD Traumatic Brain Injury and Psychological Health, Emerging Topics Research Award
DoD Traumatic Brain Injury and Psychological Health, Clinical Trial Award
FY2006 Deployed War Fighter Protection Research Program
Department of Defense (DOD) Fiscal Year 2003 (FY03) Breast Cancer Research Program (BCRP)C...
Department of Defense (DOD) Fiscal Year 2004 (FY04) Breast Cancer Research Program (BCRP) ...
More Grants from the Dept of the Army USAMRAA
DoD Traumatic Brain Injury and Psychological Health, Translational Research Award
DoD Traumatic Brain Injury and Psychological Health, Focused Program Award
DoD Traumatic Brain Injury and Psychological Health, Health Services Research Award

FederalGrants.com is not endorsed by, or affiliated with, any government agency. Copyright ©2007-2024 FederalGrants.com